Laboratory Solutions to
Support Global COVID-19 Clinical Trials

We look forward to having you join us for this informative webinar event

Virtual Event | June 11, 2020 - June 11, 2020 | 11:00 - 12:00 (GMT-05) EST Add to Calendar
Stay Informed

About This Event

The COVID-19 pandemic has impacted laboratory testing in global clinical trials of both COVID-19 and non-COVID-19 treatments. This webinar examines laboratory testing and operational considerations required in the time of COVID-19, and specifically for clinical trials studying COVID-19 treatments. To what degree will process changes remain after the pandemic subsides?

Gain insight into COVID-19 test development, and how genomics, flow cytometry, immunoassay, and bioanalysis can support COVID-19 studies. Our subject matter experts will discuss business continuity measures, such as temperature monitoring and lab space redesigns, and adaptations in robust specimen collection kit ordering and tracking, as well as sample tracking, which have increased in complexity from inter-country flight restrictions. Learn about the implications of recent surges in demand for home specimen collection and local lab data management.


  • Clinical trial testing approaches for COVID-19 and non-COVID-19 studies in the time of COVID-19
  • The impact of COVID-19 on global clinical trial laboratory testing and operations
  • Patient centricity in the time of COVID-19 

This webinar will include a Q&A session.


Patrice Hugo, Ph.D.
Immunology; Chief Scientific Officer

Dr. Patrice Hugo obtained his Ph.D. in Experimental Medicine/Immunology at McGill University and completed 5 years of post-doctoral fellowships in Immunology at the Walter Elisa Hall Institute in Australia, and at the Howard Hughes Medical Institute in Denver, Colorado. He then became a Principal Investigator leading the T-lymphocyte Unit at the Montreal Clinical Research Institute with academic appointments at McGill University and Montreal University. Throughout his academic work, Dr. Hugo focused on T-lymphocyte differentiation, self-tolerance induction, and  leukemogenesis. He worked at PROCREA BioSciences and Caprion as Chief Scientific Officer and Executive Vice President R&D, respectively. Dr. Hugo was assigned as Chief Scientific Officer at Clearstone Central Laboratories later acquired by LabCorp and became Associate Vice President and Chief Scientist at LabCorp/Covance Central Laboratories Division. Dr. Patrice Hugo joined Q2 Solutions as Chief Scientific Officer where he currently leads the global scientific strategy and is responsible for the medical affairs and scientific activities of the Central Laboratories, and the Specialty Testing Centers of Excellence worldwide including Expression Analysis Genomics, Vaccine, Biomarkers and BioAnalytical/ADME laboratories. Dr. Hugo has more than 75 peer-reviewed scientific publications. He also played an active role in a number of industry organizations, including being a member of the Board of Directors for Personalized Medicine Partnership for Cancer in Quebec, and the Steering Committee for the Biomarker Factory. He is also a member of the American Society of Clinical Oncology (ASCO) and the Society for Immunotherapy of Cancer (SITC).

Caroline Keane
Senior Vice President, Project Services

Caroline Keane is senior vice president of project services at Q2 Solutions, with leadership responsibilities for global project management, data management, study setup, investigator site support and business transformation. She has successfully led several enterprise-wide strategic initiatives focused on process optimization and delivery excellence, and serves as business sponsor for a large multi-year technology implementation project, scheduled to launch this year. Caroline sits on executive steering committees for several key customers and provides executive oversight for integrated study delivery with our parent company, IQVIA. Prior to joining Q2 Solutions in 2014, Caroline was responsible for global project delivery and site support at LabCorp Clinical Trials. She has held previous leadership positions in operations and corporate development, spanning central laboratory, bioanalysis and connected devices. 
Caroline earned a Bachelor of Science from the University of Toronto and a Master of Business Administration focused on the Management of Technology from Simon Fraser University.

Tony Brown
Vice President and General Manager, Global Central Labs

Tony Brown is vice president and general manager of global central labs, and is responsible for overseeing all aspects of global central labs operations. Previously, Tony was executive director of global operations for Quest Diagnostics' Central Laboratories business. Tony brings more than 28 years of experience in the diagnostics and central laboratory business to the joint venture.

Tony earned Bachelor of Science Degrees in finance and computer science from the State University of New York, Plattsburgh, and earned a Master of Business Administration in Health Systems Administration from Union University, Graduate Management Institute.